155 related articles for article (PubMed ID: 16019524)
1. Extracellular matrix in bone marrow can mediate drug resistance in myeloma.
Vincent T; Mechti N
Leuk Lymphoma; 2005 Jun; 46(6):803-11. PubMed ID: 16019524
[TBL] [Abstract][Full Text] [Related]
2. Hyaluronan, a major non-protein glycosaminoglycan component of the extracellular matrix in human bone marrow, mediates dexamethasone resistance in multiple myeloma.
Vincent T; Molina L; Espert L; Mechti N
Br J Haematol; 2003 Apr; 121(2):259-69. PubMed ID: 12694247
[TBL] [Abstract][Full Text] [Related]
3. Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia.
Yanamandra N; Colaco NM; Parquet NA; Buzzeo RW; Boulware D; Wright G; Perez LE; Dalton WS; Beaupre DM
Clin Cancer Res; 2006 Jan; 12(2):591-9. PubMed ID: 16428505
[TBL] [Abstract][Full Text] [Related]
4. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms.
Nefedova Y; Landowski TH; Dalton WS
Leukemia; 2003 Jun; 17(6):1175-82. PubMed ID: 12764386
[TBL] [Abstract][Full Text] [Related]
5. The tumor microenvironment as a determinant of cancer cell survival: a possible mechanism for de novo drug resistance.
Shain KH; Landowski TH; Dalton WS
Curr Opin Oncol; 2000 Nov; 12(6):557-63. PubMed ID: 11085455
[TBL] [Abstract][Full Text] [Related]
6. Targeting of adhesion molecules as a therapeutic strategy in multiple myeloma.
Neri P; Bahlis NJ
Curr Cancer Drug Targets; 2012 Sep; 12(7):776-96. PubMed ID: 22671924
[TBL] [Abstract][Full Text] [Related]
7. Integrin-mediated drug resistance in multiple myeloma.
Damiano JS; Dalton WS
Leuk Lymphoma; 2000 Jun; 38(1-2):71-81. PubMed ID: 10811449
[TBL] [Abstract][Full Text] [Related]
8. Drug resistance and drug development in multiple myeloma.
Dalton WS
Semin Oncol; 2002 Dec; 29(6 Suppl 17):21-5. PubMed ID: 12520481
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms associated with cell adhesion mediated drug resistance (CAM-DR) in hematopoietic malignancies.
Hazlehurst LA; Dalton WS
Cancer Metastasis Rev; 2001; 20(1-2):43-50. PubMed ID: 11831646
[TBL] [Abstract][Full Text] [Related]
10. Proteomic characterization of human multiple myeloma bone marrow extracellular matrix.
Glavey SV; Naba A; Manier S; Clauser K; Tahri S; Park J; Reagan MR; Moschetta M; Mishima Y; Gambella M; Rocci A; Sacco A; O'Dwyer ME; Asara JM; Palumbo A; Roccaro AM; Hynes RO; Ghobrial IM
Leukemia; 2017 Nov; 31(11):2426-2434. PubMed ID: 28344315
[TBL] [Abstract][Full Text] [Related]
11. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance.
Meads MB; Hazlehurst LA; Dalton WS
Clin Cancer Res; 2008 May; 14(9):2519-26. PubMed ID: 18451212
[TBL] [Abstract][Full Text] [Related]
12. Bone Marrow Stromal Cells-Induced Drug Resistance in Multiple Myeloma.
Ria R; Vacca A
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963513
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy induces secretion of exosomes loaded with heparanase that degrades extracellular matrix and impacts tumor and host cell behavior.
Bandari SK; Purushothaman A; Ramani VC; Brinkley GJ; Chandrashekar DS; Varambally S; Mobley JA; Zhang Y; Brown EE; Vlodavsky I; Sanderson RD
Matrix Biol; 2018 Jan; 65():104-118. PubMed ID: 28888912
[TBL] [Abstract][Full Text] [Related]
14. Old and Young Actors Playing Novel Roles in the Drama of Multiple Myeloma Bone Marrow Microenvironment Dependent Drug Resistance.
Manni S; Carrino M; Semenzato G; Piazza F
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29783691
[TBL] [Abstract][Full Text] [Related]
15. Differential gene expression analysis related to extracellular matrix components in drug-resistant RPMI-8226 cell line.
Mutlu P; Ural AU; Gündüz U
Biomed Pharmacother; 2012 Apr; 66(3):228-31. PubMed ID: 22425183
[TBL] [Abstract][Full Text] [Related]
16. Altered expression of fibronectin and collagens I and IV in multiple myeloma and monoclonal gammopathy of undetermined significance.
Tancred TM; Belch AR; Reiman T; Pilarski LM; Kirshner J
J Histochem Cytochem; 2009 Mar; 57(3):239-47. PubMed ID: 19001640
[TBL] [Abstract][Full Text] [Related]
17. BCL-X expression in multiple myeloma: possible indicator of chemoresistance.
Tu Y; Renner S; Xu F; Fleishman A; Taylor J; Weisz J; Vescio R; Rettig M; Berenson J; Krajewski S; Reed JC; Lichtenstein A
Cancer Res; 1998 Jan; 58(2):256-62. PubMed ID: 9443402
[TBL] [Abstract][Full Text] [Related]
18. Mitogen-activated protein kinase signaling causes malignant melanoma cells to differentially alter extracellular matrix biosynthesis to promote cell survival.
Afasizheva A; Devine A; Tillman H; Fung KL; Vieira WD; Blehm BH; Kotobuki Y; Busby B; Chen EI; Tanner K
BMC Cancer; 2016 Mar; 16():186. PubMed ID: 26944546
[TBL] [Abstract][Full Text] [Related]
19. HSP70 inhibition reverses cell adhesion mediated and acquired drug resistance in multiple myeloma.
Nimmanapalli R; Gerbino E; Dalton WS; Gandhi V; Alsina M
Br J Haematol; 2008 Aug; 142(4):551-61. PubMed ID: 18503584
[TBL] [Abstract][Full Text] [Related]
20. Effects of DTX3L on the cell proliferation, adhesion, and drug resistance of multiple myeloma cells.
Shen Y; Sun Y; Zhang L; Liu H
Tumour Biol; 2017 Jun; 39(6):1010428317703941. PubMed ID: 28653881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
